Karyopharm Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, KPTI, Karyopharm Therapeutics Inc, priceseries

Karyopharm Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
5.87
Close
6.06
High
6.35
Low
5.85
Previous Close
5.91
Daily Price Gain
0.15
YTD High
14.73
YTD High Date
Feb 18, 2022
YTD Low
5.83
YTD Low Date
Mar 4, 2022
YTD Price Change
-1.04
YTD Gain
-14.65%
52 Week High
14.73
52 Week High Date
Feb 18, 2022
52 Week Low
4.42
52 Week Low Date
Aug 20, 2021
52 Week Price Change
-5.03
52 Week Gain
-45.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 27. 2017
10.83
Apr 7. 2017
11.64
9 Trading Days
7.47%
Link
LONG
Aug 22. 2017
8.66
Sep 13. 2017
10.10
15 Trading Days
16.64%
Link
LONG
Jan 22. 2018
10.27
Feb 5. 2018
11.26
10 Trading Days
9.62%
Link
LONG
Feb 12. 2018
13.20
Mar 15. 2018
16.03
22 Trading Days
21.41%
Link
LONG
May 2. 2018
15.52
May 24. 2018
18.03
16 Trading Days
16.17%
Link
LONG
Aug 28. 2018
18.34
Sep 6. 2018
19.29
6 Trading Days
5.18%
Link
LONG
May 20. 2019
5.14
May 31. 2019
5.65
8 Trading Days
9.88%
Link
LONG
Jul 2. 2019
6.54
Aug 2. 2019
8.36
22 Trading Days
27.87%
Link
LONG
Sep 5. 2019
9.45
Sep 20. 2019
10.63
11 Trading Days
12.48%
Link
LONG
Oct 25. 2019
11.19
Dec 6. 2019
16.59
29 Trading Days
48.25%
Link
LONG
Dec 16. 2019
16.99
Jan 2. 2020
18.26
11 Trading Days
7.50%
Link
LONG
Feb 28. 2020
16.34
Mar 9. 2020
21.41
6 Trading Days
31.04%
Link
LONG
Apr 8. 2020
19.28
Apr 29. 2020
23.02
14 Trading Days
19.37%
Link
LONG
Jan 25. 2021
15.71
Jan 27. 2021
16.53
2 Trading Days
5.22%
Link
LONG
Jun 7. 2021
9.41
Jun 29. 2021
10.31
16 Trading Days
9.61%
Link
LONG
Feb 10. 2022
9.11
Feb 22. 2022
10.48
7 Trading Days
15.08%
Link
Company Information
Stock Symbol
KPTI
Exchange
NasdaqGS
Company URL
http://www.karyopharm.com
Company Phone
617-658-0600
CEO
Michael G. Kauffman
Headquarters
Massachusetts
Business Address
85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA 02459
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001503802
About

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading